Cargando…
Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment
PURPOSE: The phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT) pathway controls insulin sensitivity and glucose metabolism. Hyperglycemia is one of the most common on‐target adverse effects (AEs) of PI3K/AKT inhibitors. As several PI3K and AKT inhibitors are approved by the United States Food...
Autores principales: | Liu, Dazhi, Weintraub, Michael A., Garcia, Christine, Goncalves, Marcus D., Sisk, Ann Elizabeth, Casas, Alissa, Harding, James J., Harnicar, Stephen, Drilon, Alexander, Jhaveri, Komal, Flory, James H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9041081/ https://www.ncbi.nlm.nih.gov/pubmed/35212193 http://dx.doi.org/10.1002/cam4.4579 |
Ejemplares similares
-
Sodium-Glucose Cotransporter-2 Inhibitors for Hyperglycemia in Phosphoinositide 3-kinase Pathway Inhibition
por: Weintraub, Michael A, et al.
Publicado: (2023) -
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
por: Liu, Dazhi, et al.
Publicado: (2018) -
SKA3 promotes lung adenocarcinoma metastasis through the EGFR–PI3K–Akt axis
por: Hu, Dan-dan, et al.
Publicado: (2020) -
Erianin induces triple-negative breast cancer cells apoptosis by activating PI3K/Akt pathway
por: Xu, Yonggang, et al.
Publicado: (2021) -
Digoxin exerts anticancer activity on human nonsmall cell lung cancer cells by blocking PI3K/Akt pathway
por: Wang, Yingying, et al.
Publicado: (2021)